Literature DB >> 9498047

Presence of Cu/Zn superoxide dismutase (SOD) immunoreactivity in neuronal hyaline inclusions in spinal cords from mice carrying a transgene for Gly93Ala mutant human Cu/Zn SOD.

N Shibata1, A Hirano, M Kobayashi, M C Dal Canto, M E Gurney, T Komori, T Umahara, K Asayama.   

Abstract

This investigation deals with the immunocytochemical localization of Cu/Zn superoxide dismutase (SOD) in the spinal cord neurons of transgenic mice that overexpress Gly93Ala mutant human Cu/Zn SOD and demonstrate clinicopathological features similar to human amyotrophic lateral sclerosis (ALS) with Cu/Zn SOD mutation. At low magnification of light microscopy, the gray and white matter of the spinal cord of Gly93Ala mice showed more intense Cu/Zn SOD immunoreactivity than that of control mice. At higher magnification, the cytoplasm of control mice neurons displayed a distinct staining for Cu/Zn SOD, whereas the surrounding neuropil was only weakly stained. In contrast, the intensity of Cu/Zn SOD immunoreactivity in the cytoplasm of the majority of Gly93Ala mice neurons was similar to that in the neuropil. Almost all neuronal hyaline inclusions (NHIs) of Gly93Ala mice were positively immunostained by antibodies to Cu/Zn SOD, ubiquitin and phosphorylated neurofilament protein (NFP), the intensities of which were much higher in the NHIs than in the surrounding cytoplasm. In control mice, significant Cu/Zn SOD precipitation was not observed to be limited to any particular region of the neuronal cytoplasm. Intracytoplasmic vacuoles in the neuronal soma and processes of Gly93Ala mice were not stained by any of these antibodies. These results indicate that Cu/Zn SOD colocalizes with ubiquitin and phosphorylated NFP in NHIs of mice expressing mutant Cu/Zn SOD; similar findings have been shown for Lewy body-like inclusions of familial ALS patients with Cu/Zn SOD mutation. Moreover, our results point to the possibility that Cu/Zn SOD mutation may have a role in the abnormal Cu/Zn SOD accumulation in the NHIs, in association with motor neuron degeneration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9498047     DOI: 10.1007/s004010050777

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  5 in total

1.  Impaired post-translational folding of familial ALS-linked Cu, Zn superoxide dismutase mutants.

Authors:  Cami K Bruns; Ron R Kopito
Journal:  EMBO J       Date:  2007-01-25       Impact factor: 11.598

2.  Interaction of amyotrophic lateral sclerosis (ALS)-related mutant copper-zinc superoxide dismutase with the dynein-dynactin complex contributes to inclusion formation.

Authors:  Anna-Lena Ström; Ping Shi; Fujian Zhang; Jozsef Gal; Renee Kilty; Lawrence J Hayward; Haining Zhu
Journal:  J Biol Chem       Date:  2008-05-30       Impact factor: 5.157

3.  Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis.

Authors:  J A Johnston; M J Dalton; M E Gurney; R R Kopito
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

4.  Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS).

Authors:  David S Howland; Jian Liu; Yijin She; Beth Goad; Nicholas J Maragakis; Benjamin Kim; Jamie Erickson; John Kulik; Lisa DeVito; George Psaltis; Louis J DeGennaro; Don W Cleveland; Jeffrey D Rothstein
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

5.  Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis.

Authors:  Manuela Basso; Giuseppina Samengo; Giovanni Nardo; Tania Massignan; Giuseppina D'Alessandro; Silvia Tartari; Lavinia Cantoni; Marianna Marino; Cristina Cheroni; Silvia De Biasi; Maria Teresa Giordana; Michael J Strong; Alvaro G Estevez; Mario Salmona; Caterina Bendotti; Valentina Bonetto
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.